Comprehensive medication guide to {drug} including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Zenzedi is a brand-name prescription medication containing dextroamphetamine sulfate, a CNS stimulant in the amphetamine class. It is FDA-approved for treating Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients ages 3–16 and narcolepsy. It is also widely used off-label for adult ADHD.
Zenzedi is manufactured by Azurity Pharmaceuticals (formerly Arbor Pharmaceuticals) and comes as an immediate-release tablet taken 1–3 times daily. The typical dose range is 5–40 mg per day in divided doses.
Zenzedi's active ingredient, dextroamphetamine, works by increasing the release and blocking the reuptake of norepinephrine and dopamine in the brain. These neurotransmitters play key roles in attention, focus, and wakefulness. Dextroamphetamine is the dextro-isomer of amphetamine, which makes it more potent at dopamine signaling than the levo-isomer — meaning it may be more effective at improving focus with fewer peripheral side effects for some patients.
All doses are available as brand Zenzedi or generic dextroamphetamine sulfate IR tablets.
Zenzedi scores a 35 out of 100 on our findability scale, meaning it is frequently difficult to find at local pharmacies. As a less commonly prescribed brand-name dextroamphetamine product, Zenzedi is disproportionately affected by the ongoing national ADHD stimulant shortage that began in 2022. The DEA raised amphetamine production quotas by 25% in October 2025, but manufacturing has been slow to catch up with demand. Many pharmacies simply don't stock Zenzedi at all, and those that do may run out quickly.
Patients report calling 10–20 pharmacies before finding Zenzedi in stock. Using a tool like Medfinder can save hours of phone calls by checking pharmacy inventory in real time.
Struggling to find {drug} in stock? We'll call the pharmacies, sit on hold, and find you one that can fill your prescription.
Since Zenzedi is a Schedule II controlled substance, it must be prescribed by a licensed healthcare provider with DEA registration. Common prescribers include:
Note: Some telehealth platforms prescribe stimulants but may favor more common options like Adderall or Vyvanse over Zenzedi specifically.
Yes. Zenzedi is classified as a Schedule II (CII) controlled substance by the DEA. This is the highest schedule for medications with accepted medical use, reflecting amphetamine's high potential for abuse and dependence.
This classification means:
Serious side effects (seek medical attention): sudden cardiac events, new or worsening psychiatric symptoms (psychosis, mania), peripheral vasculopathy (Raynaud's phenomenon), serotonin syndrome when combined with serotonergic drugs, and seizures.
If you can't find Zenzedi in stock, consider discussing these alternatives with your doctor:
Major interactions (avoid or use extreme caution):
Moderate interactions:
Food interactions: Avoid acidic fruit juices and Vitamin C supplements near dosing time. Limit caffeine. Avoid alcohol.
Zenzedi is an effective ADHD and narcolepsy medication, but finding it in stock remains a significant challenge in 2026. With a findability score of just 35/100, patients should be prepared to check multiple pharmacies or use tools like Medfinder to locate availability in real time. Generic dextroamphetamine sulfate is more affordable and sometimes easier to find than brand Zenzedi. Talk to your doctor about the Azurity Savings Card (as low as $75/Rx for cash-paying patients) or patient assistance programs if cost is a barrier. If Zenzedi remains unavailable, alternatives like Adderall, Vyvanse, or Xelstrym may be worth discussing with your prescriber.
%2C%20Color%3DOriginal.png)
